Koskinen, 352 patient various antiandrogen prophylaxis study: 46% lower mortality [p=1], 46% lower combined mortality/ICU admission [p=1], and 11% fewer cases [p=1] https://c19p.org/koskinen
copied to clipboard
Androgen deprivation and SARS-CoV-2 in men with prostate cancer
et al., Annals of Oncology, doi:10.1016/j.annonc.2020.06.015
Retrospective 352 prostate cancer patients in Finland, showing no significant differences in COVID-19 with ADT.
|
risk of death, 45.8% lower, RR 0.54, p = 1.00, treatment 1 of 134 (0.7%), control 3 of 218 (1.4%), NNT 159.
|
|
risk of death/ICU, 45.8% lower, RR 0.54, p = 1.00, treatment 1 of 134 (0.7%), control 3 of 218 (1.4%), NNT 159.
|
|
risk of case, 11.3% lower, RR 0.89, p = 1.00, treatment 6 of 134 (4.5%), control 11 of 218 (5.0%), NNT 176.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Koskinen et al., 6/29/2020, retrospective, Finland, Europe, peer-reviewed, 7 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.